Neuroscience Research, Abbott Laboratories, 100 Abbott Park Rd., Abbott Park, IL 60064, USA.
Neuropharmacology. 2010 Sep;59(3):201-7. doi: 10.1016/j.neuropharm.2010.05.009. Epub 2010 Jun 1.
Activation of sodium channels is essential to action potential generation and propagation. Recent genetic and pharmacological evidence indicates that activation of Na(v)1.8 channels contributes to chronic pain. Herein, we describe the identification of a novel series of structurally related pyridine derivatives as potent Na(v)1.8 channel blockers. A-887826 exemplifies this series and potently (IC(50)=11nM) blocked recombinant human Na(v)1.8 channels. A-887826 was approximately 3 fold less potent to block Na(v)1.2, approximately 10 fold less potent to block tetrodotoxin-sensitive sodium (TTX-S Na(+)) currents and was >30 fold less potent to block Na(V)1.5 channels. A-887826 potently blocked tetrodotoxin-resistant sodium (TTX-R Na(+)) currents (IC(50)=8nM) from small diameter rat dorsal root ganglion (DRG) neurons in a voltage-dependent fashion. A-887826 effectively suppressed evoked action potential firing when DRG neurons were held at depolarized potentials and reversibly suppressed spontaneous firing in small diameter DRG neurons from complete Freund's adjuvant inflamed rats. Following oral administration, A-887826 significantly attenuated tactile allodynia in a rat neuropathic pain model. Further characterization of TTX-R current block in rat DRG neurons demonstrated that A-887826 (100nM) shifted the mid-point of voltage-dependent inactivation of TTX-R currents by approximately 4mV without affecting voltage-dependent activation and did not exhibit frequency-dependent inhibition. The present data demonstrate that A-887826 is a structurally novel and potent Na(v)1.8 blocker that inhibits rat DRG TTX-R currents in a voltage-, but not frequency-dependent fashion. The ability of this structurally novel Na(v)1.8 blocker to effectively reduce tactile allodynia in neuropathic rats further supports the role of Na(v)1.8 sodium channels in pathological pain states.
钠通道的激活对于动作电位的产生和传播至关重要。最近的遗传和药理学证据表明,Nav1.8 通道的激活有助于慢性疼痛。在此,我们描述了一系列结构相关的吡啶衍生物作为有效的 Nav1.8 通道阻断剂的鉴定。A-887826 就是该系列的一个范例,对重组人 Nav1.8 通道具有强大的抑制作用(IC50=11nM)。A-887826 对 Nav1.2 的抑制作用约低 3 倍,对河豚毒素敏感的钠(TTX-S Na+)电流的抑制作用约低 10 倍,对 Nav1.5 通道的抑制作用约低 30 倍。A-887826 以电压依赖性方式有效地阻断了来自大鼠小直径背根神经节(DRG)神经元的河豚毒素抗性钠(TTX-R Na+)电流(IC50=8nM)。当 DRG 神经元在去极化电位下保持时,A-887826 有效地抑制了诱发动作电位的放电,并且可逆地抑制了来自完全弗氏佐剂致炎大鼠的小直径 DRG 神经元的自发性放电。口服给予 A-887826 后,可显著减轻大鼠神经病理性疼痛模型中的触觉过敏。对大鼠 DRG 神经元中 TTX-R 电流阻断的进一步表征表明,A-887826(100nM)将 TTX-R 电流电压依赖性失活的中点大约移动了 4mV,而不影响电压依赖性激活,并且不表现出频率依赖性抑制。本数据表明,A-887826 是一种结构新颖且有效的 Nav1.8 阻断剂,可抑制大鼠 DRG TTX-R 电流,呈电压依赖性而非频率依赖性。这种结构新颖的 Nav1.8 阻断剂能够有效地减轻神经病理性大鼠的触觉过敏,进一步支持 Nav1.8 钠通道在病理性疼痛状态中的作用。